Monte Rosa Therapeutic (GLUE) Barclays 28th Annual Global Healthcare Conference summary

Platform technology and scientific differentiation

• Molecular glue degraders enable targeting of previously undruggable proteins by reshaping E3 ligase surfaces, facilitating protein-protein interactions for targeted degradation.

• Compared to heterobifunctional degraders, molecular glues do not require a binding site on the target, expanding the range of druggable proteins.

• The platform focuses on novel targets, especially in immunology and inflammation (I&I), with some oncology applications.

Pipeline progress and clinical updates

• MRT-6160 (VAV1 degrader) is licensed to Novartis, with multiple phase II trials in autoimmunity planned for 2024.

• MRT-8102 (NEK7 degrader) targets the NLRP3 inflammasome, showing strong CRP reduction and favorable safety in early studies; expanded GFORCE-1 study data expected in H2 2024.

• GFORCE-2, a phase II study for MRT-8102 in ASCVD, will start in H2 2024, focusing on longer administration and safety.

• GSPT1 program (MRT-2359) in metastatic castration-resistant prostate cancer with AR mutations showed 100% PSA response in early data; phase II signal-confirming study to begin Q3 2024.

Mechanistic insights and future directions

• NEK7 degradation blocks NLRP3 inflammasome assembly, providing sustained anti-inflammatory effects and differentiating from cytokine inhibitors.

• CRP reduction with MRT-8102 is rapid and sustained, with up to 85% reduction at week four and no rebound, outperforming some existing therapies.

• Broad pharmacodynamic effect observed across a wide dose range, supporting flexible dosing strategies.

• Additional indications under consideration include chronic gout, hidradenitis suppurativa, and pericarditis, with further guidance to be provided.